Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 2/20 | 0.67 |
| ▸ | CDC25B | P30305 | 2/20 | 0.67 |
| ▸ | CDC25C | P30307 | 2/20 | 0.67 |
| ▸ | CDK4 | P11802 | 9/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | CCND1 | P24385 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | KMT5A | Q9NQR1 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.34 |
| ▸ | S100A4 | P26447 | 1/20 | 0.33 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.31 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30834074 | 1.00 | CDC25A (0.67) | CDC25ACDC25BCDC25CCDK4KMT2A | |
| SCHEMBL2404338 | 0.94 | CDC25A (0.68) | CDC25ACDC25BCDC25CCDK4KMT2A | |
| SCHEMBL2401595 | 0.90 | CDC25A (0.82) | CDC25ACDC25BCDC25CKMT2ARAD52 | |
| SCHEMBL2401727 | 0.81 | CDC25A (0.52) | CDC25ACDC25BCDC25CCDK4KMT2A | |
| SCHEMBL1917955 | 0.81 | CDC25A (1.00) | CDC25ACDC25BCDC25CKMT2ARAD52 | |
| SCHEMBL2398380 | 0.79 | CDC25A (0.77) | CDC25ACDC25BCDC25CCDK4KMT2A | |
| SCHEMBL2404412 | 0.77 | CDC25A (0.60) | CDC25ACDC25BCDC25CKMT2ATDP1 | |
| SCHEMBL2402571 | 0.77 | CDC25A (0.73) | CDC25ACDC25BCDC25CCDK4KMT2A | |
| SCHEMBL2399099 | 0.76 | CDC25A (0.69) | CDC25ACDC25BCDC25CCDK4KMT2A | |
| SCHEMBL29360835 | 0.76 | CDC25A (0.60) | CDC25ACDC25BCDC25CCDK4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275624-A1 | INHIBITORS OF CDC PHOSPHATASES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-11-05 | — | — | US | claimed |
| EP-1831209-B1 | CDC25 PHOSPHATASE INHIBITORS | IPSEN PHARMA (FR) | 2009-08-12 | — | — | EP | claimed |
| US-10179914-B2 | CDC25A inhibitor for the treatment of drug resistant cancer or for the prevention of tumor relapse | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2019-01-15 | — | — | US | disclosed |
| US-20170247706-A1 | CDC25A INHIBITOR FOR THE TREATMENT OF DRUG RESISTANT CANCER OR FOR THE PREVENTION OF TUMOR RELAPSE | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2017-08-31 | — | — | US | disclosed |
| US-8017637-B2 | Inhibitors of cdc phosphatases | IPSEN PHARMA S.A.S. (FR) | 2011-09-13 | — | — | US | disclosed |
| US-20090275624-A1 | INHIBITORS OF CDC PHOSPHATASES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-11-05 | — | — | US | disclosed |
| EP-1831209-B1 | CDC25 PHOSPHATASE INHIBITORS | IPSEN PHARMA (FR) | 2009-08-12 | — | — | EP | disclosed |
| EP-1831209-A2 | CDC25 PHOSPHATASE INHIBITORS | Société de Conseils de Recherches et d'Applications Scientifiques SAS (S.C.R.A.S) (FR) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006067311-A2 | CDC25 PHOSPHATASE INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) SAS (FR) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247706-A1 | CDC25A INHIBITOR FOR THE TREATMENT OF DRUG RESISTANT CANCER OR FOR THE PREVENTION OF TUMOR RELAPSE | CDC25A, CDC25C, CDC25B | CDC25A 1/4885CDC25B 3/4885CDC25C 2/4885 |
| US-10179914-B2 | CDC25A inhibitor for the treatment of drug resistant cancer or for the prevention of tumor relapse | CDC25A, CDC25C, CDC25B | CDC25A 1/4885CDC25B 3/4885CDC25C 2/4885 |
| US-20090275624-A1 | INHIBITORS OF CDC PHOSPHATASES | CDC25C, CDC25A, CDC25B | CDC25A 2/4885CDC25B 3/4885CDC25C 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.